255 results about "In vitro study" patented technology

This invention relates to a novel microfluidic device and methods of using this device to conduct in vitro studies on the reaction and effects of various compounds on cells. More particularly, it relates to a method for using stop flow in a microfluidic system to study the effect of compounds on individual cells. It also provides a method for observing the effects of candidate compounds on leukocyte rolling.

An improved method of nuclear transfer involving the transplantation of donor cell nuclei into enucleated oocytes of a species different from the donor cell is provided. The resultant nuclear transfer units are useful for the production of isogenic embryonic stem cells, in particular human isogenic embryonic or stem cells. These embryonic or stem-like cells are useful for producing desired differentiated cells and for introduction, removal or modification, of desired genes, e.g., at specific sites of the genome of such cells by homologous recombination. These cells, which may contain a heterologous gene, are especially useful in cell transplantation therapies and for in vitro study of cell differentiation.

Fluidic multiwell bioreactors are provided as a microphysiological platform for in vitro investigation of multi-organ crosstalks for an extended period of time of at least weeks and months. The disclosed platform is featured with one or more improvements over existing bioreactors, including on-board pumping for pneumatically driven fluid flow, a redesigned spillway for self-leveling from source to sink, a non-contact built-in fluid level sensing device, precise control on fluid flow profile and partitioning, and facile reconfigurations such as daisy chaining and multilayer stacking. The platform supports the culture of multiple organs in a microphysiological, interacted systems, suitable for a wide range of biomedical applications including systemic toxicity studies and physiology-based pharmacokinetic and pharmacodynamic predictions. A process to fabricate the disclosed bioreactors is also provided.

Isolated mixed populations of fetal pulmonary cells, engineered three-dimensional tissue constructs of these cells, and uses thereof in identifying therapeutic agents which augment, repair, and / or replace dysfunctional native lung and to perform in vitro studies such as pharmaceutical screening, models for lung development and disease and characterization of chemical or mechanical injury are provided.

The present invention is directed to improved therapeutics against receptors within the EGFR / ErbB / HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.

The present invention provides compounds useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role.

An improved method of nuclear transfer involving the transplantation of differentiated donor cell nuclei into enucleated oocytes of a species different from the donor cell is provided. The resultant nuclear transfer units are useful for the production of isogenic embryonic stem cells, in particular human isogenic embryonic or stem cells. These embryonic or stem-like cells are useful for producing desired differentiated cells and for introduction, removal or modification, of desired genes, e.g., at specific sites of the genome of such cells by homologous recombination. These cells, which may contain a heterologous gene, are especially useful in cell transplantation therapies and for in vitro study of cell differentiation. Also, methods for improving nuclear transfer efficiency by genetically altering donor cells to inhibit apoptosis, select for a specific cell cycle and / or enhance embryonic growth and development are provided.

The present invention relates to growth hormone-releasing hormone (GHRH) analogues. More particularly, the invention relates to synthetic GHRH analogues of amino acids or more, exhibiting concomitantly an increased resistance to proteolysis and high binding affinity to human GHRH receptor in in vitro studies, in comparison with human native GHRH (1-29)NH2. The present invention also relates to a pharmaceutical composition comprising any one of said GHRH analogues and to the use of these analogues for specific stimulation of in vivo GH release as well as preparation of a drug in the treatment of GH deficiency-related conditions. The present invention also provides for a method for initiating GHRH-induced biological actions in a mammal.

A novel electrically conductive polymer composite composed of polycaprolactone fumarate-polypyrrole (PCLF-PPy) for applications in nerve regeneration is disclosed. The synthesis and characterization of PCLF-PPy and in vitro studies showing PCLF-PPy supports both PC12 cell and Dorsal Root Ganglia neurite extension. PCLF-PPy composite materials were synthesized by polymerizing pyrrole in pre-formed scaffolds of PCLF resulting in an interpenetrating network of PCLF-PPy. PCLF-PPy composite materials possess electrical conductivity up to 6 mS cm−1 with compositions ranging from 5-13.5 percent polypyrrole of the bulk material. Surface topographies of PCLF-PPy materials show microstructures with a RMS roughness of 1195 nm and nanostructures with RMS roughness of 8 nm. PCLF-PPy derivatives were synthesized with anionic dopants to determine effects on electrical conductivity and to optimize the chemical composition for biocompatibility. In vitro studies using PC12 show PCLF-PPy composite materials induce a higher cellular viability and increased neurite extension compared to PCLF. PCLF-PPy composites doped with either naphthalene sulfonic acid or dodecyl benzene sulfonic acid are determined to be the optimal materials for electrical stimulation. In vitro studies showed significant increases in percentage of neurite bearing cells, number of neurites per cell and neurite length in the presence of ES compared to no ES. Additionally, extending neurites were observed to align in the direction of the applied current. Electrically conductive PCLF-PPy scaffolds possess material properties necessary for application as nerve conduits. Additionally, the capability to significantly enhance and direct neurite extension by passing electrical current through PCLF-PPy scaffolds renders them even more promising as future therapeutic treatments for severe nerve injuries.

The present invention reveals a method for developing agent-based simulation systems that are capable for the modeling and simulation of a systematic and analytical approach to a host-pathogen interaction. This methodology may enable users to explore “what if” scenarios and develop predictive data that may be used in experimental design and the testing of hypotheses of disease states. Using an in silico testing environment, the in silico approach helps combine knowledge of disease states that may be obtained from various sources, such as in vitro studies and in vivo studies, without requiring users to perform all necessary experimentation.

The present invention relates to a novel hepatocyte-like cell population derived from hBS cells and to the potential use of such heopatocyte-like cells in e.g. medical treatment, drug screening and toxicity testing. Furthermore, the invention relates to hepatoblast-like cells that may have suitable characteristics so that they can be used for the same applications as the hepatocyte-like cells and that furthermore may be used in in vitro studies of hepatogenesis such as early hepatogenesis or hepato-regenerative disorders. Both the hepatocyte-like and the hepatoblast-like cells according to the invention express drug transporter and / or drug metabolising characteristics either at the gene or protein expression level.

The invention provides a multilayer tubular structural cell culture bracket as well as a preparation method and use thereof. The bracket comprises a macromolecular elastic thin film layer and a macromolecular fixed layer attached to the macromolecular elastic thin film layer. The macromolecular elastic thin film layer is elastic, so that the bracket is automatically crimped to a multilayer tubular structure. The preparation method of the cell culture bracket comprises the following steps of: preparation of the macromolecular elastic thin film layer; preparation of the macromolecular fixed layer; drawing the macromolecular elastic thin film layer and attaching the macromolecular elastic thin film layer to the macromolecular fixed layer; and forming the tubular structure. The use is that a method for distributing single / multiple cells in a lamellar manner in the multilayer tubular structural cell culture bracket is provided, and use for preparing a three-dimensional tubular structure with single / multiple cells distributed in a lamellar manner by the method. The bracket is used for simulating human organ with multiple cells distributed in the lamellar manner of blood vessel or intestinal tract, repairing diseased or damaged organs and being used as an in vitro study model.

The invention provides an inducing culture method for regulatory T cells and relates to an inducing culture method for regulatory gamma delta T cells. In the method, cell factors are applied and deoxyribonucleic acid (DNA) demethylated medicament decitabine is combined so as to cooperatively induce the generation of the regulatory gamma delta T cells, and an enrichment process of magnetic cell sorter (MACS) positive sorting is adopted; after enrichment, detections of cell growth state and activity are carried out so as to ensure the next experience. The method has the advantages of simple and practicable inducing and enrichment processes, short period, low cost, high inducing efficiency and good repeatability; and after enrichment, cell activity is good, the quantity and activity of cells can ensure the next in vivo and in vitro studies, thereby providing a good study platform for defining the biological characteristics of the gamma delta T cells. Thus, the method has a good popularization value.

The invention discloses an anti-tumor controlled release nanocomposite and a preparation method thereof. The nanocomposite utilizes nano diamonds after carboxylation treatment as carriers, and comprises adsorption enzyme self degradation chains and cell-penetrating peptides. The preparation method is implemented as follows: dispersing nano diamonds after carboxylation treatment of a strong acid in a dimethyl sulfoxide aqueous solution, adding an anti-tumor drug connected with a self degradation chain, and stirring under room temperature to obtain a composite; and dispersing the obtained composite in water, adding the cell-penetrating peptides, and stirring and drying at room temperature to obtain the anti-tumor controlled release nanocomposite. The nano carrier composite in the invention is simple and convenient in preparation, has no toxicity and pollution, and is easy for industrialization. In vitro research shows that the composite can realize controlled release of an anti-tumor drug, enhance the killing effect of the drug on tumors, and provide a new material and method for drug transport.

Disclosed are compositions and corresponding methods for treating fibrocystic breast disease or other breast-related disease or condition. The compositions comprise, per serving or dose, from zero to about 400 μg selenium, from about 100 mg to about 6000 mg gamma linolenic acid, and about 0.15 mg to about 5 mg iodine, with nutritional embodiments further comprising one or more of protein, fat, carbohydrate, vitamins, and minerals and providing from about 50 to about 1000 kcal of energy per severing or dose. Also disclosed are in-vitro studies showing that certain combinations of gamma linolenic acid, iodine, and / or selenium may 1) inhibit breast cancer or fibrocystic cell proliferation, 2) reinforce the function of tight junctions of endothelial cells and of mammary epithelial cells in estrogen-sensitive conditions, and 3) reduce the risk of vascular invasion by breast cancer cells.

Fluidic multiwell bioreactors are provided as a microphysiological platform for in vitro investigation of multi-organ crosstalks with microbiome for an extended period of time of at least weeks and months. The platform has one or more improvements over existing bioreactors, including on-board pumping for pneumatically driven fluid flow, a redesigned spillway for self-leveling from source to sink, a non-contact built-in fluid level sensing device, precise control on fluid flow profile and partitioning, and facile reconfigurations such as daisy chaining and multilayer stacking. The platform supports the culture of multiple organs together with microbiome in a microphysiological, interacted systems, suitable for a wide range of biomedical applications including systemic toxicity studies and physiology-based pharmacokinetic and pharmacodynamic predictions. A process to fabricate the bioreactors is also provided.

Hydroxyapatite (HAp) is widely accepted as bone graft substitutes for clinical application. A novel method is to synthesize an applicable HAp nanoparticles which emit fluorescence or maintain magnetic property with quenching. The present invention is related to utilize CdSe / ZnS or magnetic nano particles as the nuclei for the growth of HAp crystal. The resulted HAp nanoparticles maintain the fluorescent or magnetic characteristics of CdSe QDs or magnetic nanoparticles and exhibit a shell structure of HAp which is recognized by the biological environment. The HAp nanoparticles emit fluorescence or maintain magnetic property which is useful for tracking and could find future clinical applications especially when employed as the tool for in vitro study of bone tissue engineering.

This application invention discloses bioartificial proximal tubule device, constructed by preparing a decellularized biological matrix, seeding the biological matrix with mammalian kidney-derived cells and optionally mammalian endothelial cells. The device may then be cultured statically or matured using bioreactor culture to allow differentiation of the kidney cells into functioning proximal tubule cells. The device is capable of carrying out proximal tubule functions. The application also describes various methods of making the proximal tubule devices. The application also further describes methods of use of bioartificial proximal tubule devices for e.g. in vitro studies of tubule cell transport, toxicity effects of various compounds or pharmaceutical compound screening.

The invention provides an establishment of humanized three-dimensional intestinal mucosa model and an application thereof. The model improves a traditional Caco-2 monolayer cell model mainly based on normal physiological structure characteristics of small intestinal epithelium, wherein on basis of adding extracellular matrix, the Caco-2 cells are co-cultured with mucus-secreting cells, interstitial cells and immune cells for a period of time to form a three-dimensional intestinal mucosa model being similar with structure and function of the small intestinal epithelium in vivo. By using the model, a membrane permeating capability at small intestine epithelium as well as a metabolism degree of oral drug molecules can be predicted. The model is mainly used for researching transmembrane transportation and absorption, and metabolism process of medicament molecules at the small intestine in vitro.

Described herein are compositions and methods related to use of cardiosphere-derived cells and their extracellular vesicles, such as exosomes and microvesicles, for achieving anti-aging and rejuvenation. This includes discoveries for effects on heart structure, function, gene expression, and systemic parameters. For animal studies, intra-cardiac injections of neonatal rat CDCs was compared to in old and young rats including evaluation of blood, echocardiographic, haemodynamic and treadmill stress tests. For in vitro studies, human heart progenitors from older donors, or cardiomyocytes from aged rats were exposed to human CDCs or cardiosphere derived cell (CDC) derived exosomes (CDC-XO) from pediatric donors. CDCs and CDC-XOs were capable of effectuating youthful patterns of gene expression in the hearts of old, along with a variant of physiological and function benefits, including elongation of telomere length. Together, these results indicate capacity of CDCs and CDC-XO to ward off the effects of aging through rejuvenation.

A system and method for analyzing the dynamics of fluid layers on contact lenses utilizes phase shifting interferometry to quickly and accurately model the time-evolution of the fluid layers. The system and method are utilized for in vitro studies.

The invention discloses a separation method and application of hepatic cells peripheral to pig portal veins or hepatic cells peripheral to hepatic veins. By means of the method, a great number of hepatic cells peripheral to the portal veins or hepatic cells peripheral to the hepatic veins which are high in activity can be separated out of a pig liver, the obtained cells can maintain good morphological characteristics, hepatocellular functions and cell multiplication activity of primary hepatic cells, and a basis is provided for separation and identification of the hepatic cells peripheral to the portal veins or the hepatic cells peripheral to the hepatic veins, in vitro study on cell metabolism differences of the hepatic cells peripheral to the portal veins or the hepatic cells peripheral toward the hepatic veins and deeper exploration on liver nutrient substance metabolism.

The invention discloses a method for quickly constructing an IBV (Avian Infectious Bronchitis Virus) reverse genetic strain, and belongs to the technical field of coronavirus reverse genetics. The constructing method comprises the following steps: quickly completing construction containing IBV genomic full-strength cDNA (Complementary Deoxyribose Nucleic Acid) clone by taking a BAC (Bacterial Artificial Chromosome) vector as a framework and applying an in-vitro homologous recombination technology, directly transfecting cells by a constructed recombinant plasmid, and transcribing in the cells, thus obtaining a transcript having infectivity; completing virus packaging; inoculating SPF (Specific Pathogen Free) chick embryo to a mixed solution of the cells and a culture medium and passing from generation to generation, thus obtaining the IBV reverse genetic strain. The constructing method disclosed by the invention has the advantages of simple operation and high positive cloning efficiency, the obtained IBV reverse genetic strain has passage stability, and an effective tool is provided for researching pathogenesis of the virus in vitro, developing a novel vaccine and the like; according to the method disclosed by the invention, transcription is carried out in the cells by utilizing a CMV (Cytomegalovirus) promoter added on a 5' terminal, and the rescue efficiency of the virus is greatly increased by utilizing an HDVR (Hepatitis Delta Virus Ribozyme) sequence added on a 3' terminal.

Described herein are growth hormone-releasing hormone (GHRH) analogs and uses for such analogs. In some embodiments, growth hormone related diseases may be treated with one or more synthetic GHRH analogs of 29 amino acids or more, exhibiting concomitantly an increased resistance to proteolysis and high binding affinity to human GHRH receptor in in vitro studies, in comparison with human native GHRH (1-29)NH2.

Disclosed are living, three-dimensional tissue constructs for in vitro scientific and medical research, arrays thereof, and methods of making said tissues and arrays.

The invention discloses a method for building a dairy cattle breast acinus lactation model in vitro, and relates to a method for building a lactation model in vitro. The method solves the problem of low authenticity of in-vivo environment caused by taking a mammary epithelial cell as a research carrier in the existing in-vitro study of the lactation function of the dairy cattle breast. The method comprises the following steps: 1, preparing a tissue culture plate of matrix gel; 2, digesting primary cultured dairy cattle mammary epithelial cell gestated for 4 months by adopting pancreatin and EDTA, and collecting cells after centrifugalization; 3, preparing cell suspension and diluting; and 4, adding the cell suspension into the tissue culture plate of the matrix gel, culturing for 15 days in an incubator to finish the building. The artificial building process of the dairy cattle breast acinus lactation model built by the invention is a simulation process of in-vitro simulation of a galactemia protective screen; and a three-dimensional acinus structure thereof can truly simulate in-vivo situation, has the same lactation function and biological characteristics as the breast acinus in a ruminant, and has high authenticity of in-vivo environment simulation.

The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer.

The invention discloses an application of N-alkanoyl cordycepin in preparing drugs for treating tumor diseases. An in vitro study result shows that, compared with cordycepin, the N-alkanoyl cordycepin has stronger antineoplastic activity, and can be prepared into highly-effective and safe antineoplastic drugs, is used for treating the tumor diseases such as leukaemia, liver cancer, bladder cancer and breast cancer and the like, and has good application prospect.

The invention discloses a human glioma cell line. The preservation number of the human glioma cell line in the China General Microbiological Culture Collection Center is CGMCC NO.16693, and the preservation date is: November 07, 2018. The human glioma cell line of the invention can be stably multi-passaged, has tumorigenicity, can be prepare into a tumor animal model, and can be used for researchand development of human glioma diagnostic reagents, screening of human glioma drugs, and in vitro-studying of human gliomas. Moreover, the present invention differentiates glioma stem cells into glioma cells so as to firstly reduce the number of hetero cells, and after the glioma stem cells are differentiated into the glioma cells, the growth rate is fast, the proliferative ability is strong, andthe characteristics of pathological tissues of brain glioma is retained.